ArticleGynecologic oncology reports2019

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Elizabeth K Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.